drugset / Trial / NCT02276300

HER2-Peptide Vaccination of Patients With Solid Tumors

NCT02276300

Phase 1 Completed 2 enrolled Technical University of Munich
NaSingle-groupOpen-labelTreatment

Summary

Investigation of peptide vaccination targeting HER2/neu in patients with metastasized breast or gastric cancer with moderate HER2/neu expression.

Timeline

Start
2014-12
Primary completion
2017-07-18
Completion
2018-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject HER2-Peptid-Vakzine Vaccine
Background Cyclophosphamide Other / unclassified
Background Imiquimod Other / unclassified
Background sargramostim Protein / enzyme biologic